Gothenburg and San Francisco, CA May 24, 2018:POA Pharma Scandinavia AB (“POA”), a market oriented Boutique Healthcare Company, working in
POA Pharma Scandinavia AB signs distribution agreement with Darou Darman Kian Co for marketing and sale of POA Pharma´s metabolic
POA Pharma Scandinavia AB expands its partnership with Metabol Med to include exept the IEM products also the Antisecretory Factor
Cetraxal Comp øredråper som POA Pharma har distribuert i Danmark siden 2013 på vegne av Salvat Laboratorios, har nå fått
POA Pharma Scandinavia AB and MERUS LABS INTERNATIONAL INC., expands there existing Promotion & Distribution Agreements for EMSELEX®/ENABLEX® and
POA Pharma Scandinavia AB signs distribution agreement with Galen Limited for marketing and sale of POA Pharma´s metabolic product portfolio
MARS 2011 – MARS 2016. POA Pharma Scandinavia AB celebrating it's first five years! March 1, 2011 POA was
POA Pharma Scandinavia AB signs distribution agreement with FederalMed, Buenos Aires, Argentina for marketing and sale of POA Pharma´s products
POA Pharma Scandinavia AB and MERUS LABS INTERNATIONAL INC., expands there existing Promotion & Distribution Agreements for EMSELEX®/ENABLEX® with
2015 The year that was: Continued success for POA Pharma and international breakthrough for our Metabolic range of products.